David Hoang
Stock Analyst at Deutsche Bank
(4.74)
# 663
Out of 4,988 analysts
123
Total ratings
59.3%
Success rate
30.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Downgraded: Hold | $90 → $46 | $39.75 | +15.72% | 10 | Sep 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Hold | $120 | $97.71 | +22.81% | 1 | Aug 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $287 → $300 | $240.74 | +24.62% | 8 | Aug 26, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $135 → $127 | $90.25 | +40.72% | 5 | Aug 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $37 → $38 | $27.29 | +39.25% | 11 | Aug 25, 2026 | |
| NBIX Neurocrine Biosciences | Rated: Hold | $190 → $165 | $146.23 | +12.84% | 12 | Aug 13, 2026 | |
| HRMY Harmony Biosciences Holdings | Rated: Hold | $36 → $39 | $42.02 | -7.19% | 8 | Aug 5, 2026 | |
| KYMR Kymera Therapeutics | Initiated Coverage: Hold | $120 | $117.75 | +1.91% | 1 | Jul 29, 2026 | |
| DNLI Denali Therapeutics | Rated: Buy | $31 → $35 | $19.72 | +77.48% | 10 | Jul 16, 2026 | |
| BHVN Biohaven | Rated: Buy | $65 → $20 | $13.62 | +46.84% | 2 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $420 → $374 | $298.95 | +25.10% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $281 → $280 | $207.78 | +34.76% | 9 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $14 | $20.11 | -30.38% | 23 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $45 | $43.39 | +3.71% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $2.65 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $8.91 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $3.09 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $239.56 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $66.48 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $10.73 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $0.5683 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $336.67 | n/a | 1 | Mar 12, 2020 |
Xenon Pharmaceuticals
Sep 18, 2026
Downgraded: Hold
Price Target: $90 → $46
Current: $39.75
Upside: +15.72%
Rhythm Pharmaceuticals
Aug 27, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $97.71
Upside: +22.81%
Jazz Pharmaceuticals
Aug 26, 2026
Reiterated: Buy
Price Target: $287 → $300
Current: $240.74
Upside: +24.62%
Spyre Therapeutics
Aug 26, 2026
Reiterated: Buy
Price Target: $135 → $127
Current: $90.25
Upside: +40.72%
ACADIA Pharmaceuticals
Aug 25, 2026
Reiterated: Buy
Price Target: $37 → $38
Current: $27.29
Upside: +39.25%
Neurocrine Biosciences
Aug 13, 2026
Rated: Hold
Price Target: $190 → $165
Current: $146.23
Upside: +12.84%
Harmony Biosciences Holdings
Aug 5, 2026
Rated: Hold
Price Target: $36 → $39
Current: $42.02
Upside: -7.19%
Kymera Therapeutics
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $117.75
Upside: +1.91%
Denali Therapeutics
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $19.72
Upside: +77.48%
Biohaven
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $13.62
Upside: +46.84%
Jun 2, 2026
Reiterated: Buy
Price Target: $420 → $374
Current: $298.95
Upside: +25.10%
May 5, 2026
Rated: Buy
Price Target: $281 → $280
Current: $207.78
Upside: +34.76%
Mar 26, 2026
Reiterated: Sell
Price Target: $12 → $14
Current: $20.11
Upside: -30.38%
Nov 13, 2025
Reiterated: Buy
Price Target: $52 → $45
Current: $43.39
Upside: +3.71%
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $2.65
Upside: n/a
Jul 17, 2024
Reiterated: Buy
Price Target: $16
Current: $8.91
Upside: n/a
Mar 6, 2024
Reiterated: Buy
Price Target: $16
Current: $3.09
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $239.56
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $66.48
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $10.73
Upside: n/a
Sep 30, 2020
Reiterated: Buy
Price Target: $19
Current: $0.5683
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $336.67
Upside: n/a